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         18th October 2012  
Dear Home Secretary,  
 
Further consideration of the synthetic cannabinoids 
 
In July 2009 the Advisory Council on the Misuse of Drugs (ACMD) provided advice 
on harmful synthetic compounds (synthetic cannabinoid receptor agonists). These 
compounds had been identified in samples of smoking mixes such as „Spice‟ and 
have a pharmacology similar to that of cannabis1. At the time, these previously 
unreported compounds were outside the control of the Misuse of Drugs Act (1971). It 
was concluded that these novel substances contained compounds with the potential 
for harm, similar to the harms of cannabis. Therefore, the ACMD recommended the 
compounds considered in that review should be made Class B and placed in 
Schedule I of the Misuse of Drugs Regulations (2001) under a generic definition.  
 
Given the wide range of compounds reported in the literature, the ACMD proposed 
five generic definitions for the synthetic cannabinoid agonists and five substances 
listed by name. The purpose of the generic definitions was to control similar 
compounds that would have associated harms that could be introduced at a later 
date. The cannabinoids targeted for control under these generic definitions were CB1 
receptor agonists, identified by their ability to bind to this receptor. The CB1 receptor 
in the brain mediates the psychoactive effects of the principle active compounds in 
cannabis (Tetrahydrocannabinol (THC) and Cannabinol (CBN)). 
 
The ACMD‟s previous advice made clear that generic control for these compounds 
would likely require updating as those intent on producing such compounds find 
ways to circumvent the legislation.  
                                                 
1 http://www.homeoffice.gov.uk/acmd1/acmd-report-agonists?view=Binary  
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At present, an ever increasing number of compounds are being promoted by internet 
retailers as legal versions of, or alternatives to, controlled drugs. Websites vary 
greatly in their quality, from reliable sources to „rip-off‟ sites, but certain themes in 
their offerings are apparent. For those drug groups which are controlled in the UK by 
generic legislation, such as the synthetic cannabinoids, gaps in the generic controls 
are being exploited which permit „designer‟ versions (specifically formulated to have 
certain effects and avoid legislation) to be offered. 
 
As with all „legal highs‟ the ACMD would caution the correlation of „brand name‟ to 
constituent compounds – these are rarely consistent and compounds may be 
different to those advertised on the packet or at point of sale. This is an important 
point when considering the reporting of brands for sale without supporting analysis.  
 
Test purchasing from UK forensic and intelligence units, including reports from 
Guernsey and the Isle of Man, indicates that there are a number of synthetic 
cannabinoids outside of existing legislation that are available for purchase through 
the internet. Many of the mixtures available under different brand names contain the 
same compounds, for example AM2201 has been identified in „Black Mamba‟, 
„Annihilation‟, „Tai High Hawaiian Haze‟ and „Bombay Blue Extreme‟.  
 
The compounds are generally available as ingredients of smoking products, but are 
also available from websites as pure compounds which purchasers can combine 
with herbal materials to produce their own smoking mixtures. 
 
Prevalence of the synthetic cannabinoids 
Synthetic cannabinoids are an issue of concern internationally. The ACMD 
understands that an estimated total of 2,977 reports of synthetic cannabinoids were 
submitted to State and local forensic laboratories in the United States from 1 January 
to 31 December 2010. This is a considerable increase from the estimated 15 
synthetic cannabinoid reports identified during 2009 (in part this may be due to 
increased detection, and therefore not prevalence). However, the active compounds 
at the time of seizure cannot anyway be readily identified.   
 
Data from the Home Office Forensic Early Warning System (FEWS) in July 2012 
included results from a test purchasing exercise showing the presence of 
uncontrolled synthetic cannabinoids, such as AM2201, RCS-4 and UR-144, in 
substances on sale via the internet. In addition, the FEWS has identified AM-2201 in 
samples recovered from attendees at music festivals during the summer months of 
2012.  Seizures received up to July 2012 from Jersey have indicated a number of 
compounds found in a variety of named brands.      
 
Two seizures from Scotland (Strathclyde police), marketed as „Annihilation‟ and 
analysed in June, have been found to contain un-controlled cannabinoids (AM-2201, 
MAM-2201 and UR144). In addition to these compounds, one sample contained the 
controlled analog of JWH -122.    
 
Information has been collated through the Home Office Drugs Early Warning System 
(July 2012) from National Treatment Agency local teams. Several nil responses were 
received from local areas; however, there were also a significant number of reports 
from partnership teams of anecdotal user reports, test purchases and forensic 
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testing.  In summary, the information made available indicates a trend towards 
increased availability and use of synthetic cannabinoids that are currently outside 
legal control in the UK.  
 
It should be noted that detection of novel synthetic cannabinoids is potentially an 
issue, as police dogs are not trained to detect the substances and there is no routine 
urine test currently available for employment drug testing and testing of arrestees 
and prisoners. 
 
Chemistry and pharmacology 
When the UK‟s generic controls on synthetic cannabinoids were developed in 2009, 
they were based on the published research of JW Huffman‟s research team (the 
team developed many of the JWH compounds) of a number of other compounds 
which were known at the time. A number of modifications of Huffman‟s basic 
structures have since appeared and fall outside the UK controls. These are based on 
other published research, such as the work of Alexandros Makriyannis at North 
Eastern University who developed the „AM‟ range of compounds. The USA 
“Synthetic Drug Control Act 2012” defines synthetic cannabinoids (known in the USA 
as cannabimimetic agents) as “any substance that is a cannabinoid receptor type 
CB1 agonist as demonstrated by binding studies and functional pharmacological 
tests”. 
 
Modifications of chemical structure noted since the 2009 report include: 
 Substitution with halogen atoms on the side chain attached to the indole 
nitrogen atom (for example AM 694, AM 2201). It appears that such 
modifications can enhance potency. The onset of psychoactive effects of 
AM2201 are cited as occurring rapidly and may last for up to 3 hours 
(ReDNET, 2012).  
 Modification of the indole nitrogen substitution into a methylpiperidin-2-yl 
structure (AM 1220, AM 2233). 
 Use of a benzoylindole core structure (AM-694, RCS-4). This structure was 
not included in the 2009 generic controls. 
 Replacement of the benzoyl/naphthoyl structure by an adamantoyl group (AB-
001, AM-1248). 
 Replacement of the benzoyl/naphthoyl structure by a 
tetramethylcyclopropylcarbonyl group (UR-144, AB-034). 
 
Other variants are appearing, however, current knowledge indicates that many of 
these compounds do not seem to be particularly psychoactive and/or are primarily 
CB2 agonists, rather than CB1, and so are not anissue that presently needs to be 
addressed.  
 
Examples of synthetic cannabinoids incorporating the above modifications, together 
with CB1 binding data (where available), seizure data and availability are listed in 
Annex B. 
 
In structures containing naphthoyl and adamantoyl groups, positional isomers may 
also be exploited and, as identification of a particular positional isomer could impose 
an unnecessary burden on forensic providers, we propose broadening the definitions 
of controlled compounds of these types to include all possible structures. 
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Physical Harms  
There is limited data available on the patterns of acute harm associated with the use 
of synthetic cannabinoid receptors agonists. AM2201 has psychoactive effects and 
anecdotal user reports suggest that it can produce severe adverse effects: increased 
heart rate, panic attacks and convulsions (RedNet, 2012). Recently, there has been 
a report of an individual who smoked „black mamba‟ and presented to an Emergency 
Department with convulsions. Analysis of biological samples confirmed that the 
convulsions were due to AM2201 (McQuade, 2012). A police report from a central 
England force details three separate incidents in early 2012 that resulted in the 
hospitalisation of five young people who had taken „Black Mamba‟. However, there 
was no toxiciological screening of blood/urine samples to be able to determine which 
synthetic cannabinoid receptor agonists were responsible and/or to exclude the use 
of other drugs. The ACMD notes that the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) published a briefing paper that identifies potential harms 
(EMCDDA, 2011). 
 
With regard to the product branded „Annihilation‟ (see above for analytical chemistry) 
Strathclyde Police issued a public health warning following 13 people whom were 
taken to hospital between July and October this year. The ACMD are not aware of 
any deaths linked to the substance branded as „Annihilation‟.  
 
Tomiyama and Funada (2011) reported that the synthetic cannabinoids CP-55,940, 
CP-47,497 and CP-47,497-C8 were cytotoxic to NG 108-15 cells in tissue culture, 
and the effects were prevented by the CB1 antagonist AM251, but not by the CB2 
antagonist AM630. If this has any relevance to human users, it needs to be 
established.  
 
In the USA synthetic cannabinoids are reported to have resulted in nationwide 
emergency department visits for severe agitation, sympathomimetic toxicity, and 
death (Rosenbaum et al, 2012). Texas Poison Centres recorded 464 cases of 
cannabinoid-related toxicity in 2010, the most common features being tachycardia, 
agitation, drowsiness, vomiting, hallucinations and nausea (Forrester et al, 2011). 
 
There is very limited data available on chronic toxicity and dependence associated 
with the use of synthetic cannabinoid receptor agonists. However there have been 
isolated reports of acute withdrawal associated with cessation of long-term use of 
these products suggesting their use may be associated with dependence 
(Zimmermann, 2009). There have also been reports of psychosis and other 
psychiatric presentations associated with their use (Every-Palmer, 2010, Every-
Palmer, 2010, Benford, 2011, Tung, 2012), however, it is too early to be able to 
determine the role of synthetic cannabinoid receptor agonists in the symptoms 
reported in these presentations.  
 
The National Poisons Information Service (NPIS) is a network of specialist poisons 
information units commissioned by the Health Protection Agency. The purpose of the 
NPIS is to assist the NHS in poisons management of patients. During the period 1st 
January to 30th June 2012 there were 532 accesses (web site) to Toxbase2 under 
                                                 
2
 The primary clinical toxicology database of the NPIS 
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the term „synthetic cannabinoids‟. Of these, 356 were related to synthetic 
cannabinoid agonists not currently controlled in the UK and 334 were to the page on 
„Black Mamba‟. The data show that enquiries about synthetic cannabinoids have 
increased over time.  
 
Social Harms 
Evidence concerning the social harms of the synthetic cannabinoids is scarce and 
there is little in the scientific literature because of their relatively recent appearance.  
 
The Crime Survey for England and Wales – Drug Misuse Declared 2011/12 
highlights that 0.1% of 16 to 59 year olds reported using „Spice‟ and other 
cannabinoids in the last year. For 2010/11, the figure was 0.2%. It is reasonable to 
expect that the societal harms would be comparable to those of cannabis.   
 
FRANK 
The FRANK website provides information about synthetic cannabinoids. It provides 
details of appearance, use, effects and the legal situation.  The information suggests 
it is very likely that synthetic cannabinoids will produce harmful effects similar to 
those associated with THC and CBN (the active ingredients of cannabis) because of 
the way the chemicals in synthetic canabinoids work. The information also cautions 
that many synthetic cannabinoids are new substances and so they may have further 
unknown effects. 
 
Recommendations 
 
Recommendation 1 
The ACMD recommends that the substances detailed in Annex A, herein termed 
synthetic cannabinoids, have potential harms commensurate with those of cannabis 
and should, therefore, be classified and controlled under the Misuse of Drugs Act 
(1971) as Class B (2001) under an extended generic definition3.   
 
Recommendation 1 above represents an extension to the ACMD‟s 2009 advice on 
the synthetic cannabinoids.   
 
Recommendation 2 
The ACMD has conducted a non-exhaustive search of the potential uses of  
synthetic cannabinoids and therefore recommends that those compounds covered 
by the proposed generic definition (listed in Annex A) are placed in Schedule 1 of the 
Misuse of Drugs Regulations (2001) on the grounds they have no recognised 
medicinal use. 
 
Recommendation 3 
The ACMD has carefully considered the available legislative vehicles available in 
making this recommendation for full control under the Misuse of Drugs Act 1971. In 
making this recommendation it is important that there is on-going active monitoring 
of the prevalence and harms of the synthetic cannabinoids listed. The ACMD will 
                                                 
3 Annex A also includes a small correction to the chemical nomenclature in one of the generic 
definitions currently provided for in the legislation.  
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look to conduct this through relevant channels and will provide you with further 
advice should there be substantive developments.  
 
Recommendation 4 
Public health messaging, through FRANK, should be kept up to date based on the 
most recent information available.  
 
 
Yours sincerely, 
 
 
 
 
Professor Les Iversen 
 
Cc:  
Minister of State for Crime Prevention  
Parliamentary Under Secretary of State for Health 
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Annex A.  
 
Extended generic definition of the synthetic cannabinoid receptor based 
agonists.  
 
  
Proposed changes to the current generic definitions: 
Any compound structurally derived from 3-(1-naphthoyl) indole, 3-(2-naphthoyl) 
indole, 1H-indol-3-yl-(1-naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by 
substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, 
cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-
yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole 
ring to any extent and whether or not substituted in the naphthyl ring to any extent. 
 
Any compound structurally derived from 3-(1-naphthoyl)pyrrole or 3-(2-
naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, 
haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-
methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further 
substituted in the pyrrole ring to any extent and whether or not substituted in the 
naphthyl ring to any extent. 
 
Any compound structurally derived from 1-(1-naphthylmethylene)indene or 1-(2-
naphthylmethylene)indene by substitution at the 3-position of the indene ring by 
alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 
(N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further 
substituted in the indene ring to any extent and whether or not substituted in the 
naphthyl ring to any extent. 
 
Any compound structurally derived from 3-phenylacetylindole by substitution at the 
nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, 
hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-
(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any 
extent and whether or not substituted in the phenyl ring to any extent. 
 
Proposed additional generic definitions (to that above): 
Any compound structurally derived from 3-benzoylindole by substitution at the 
nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, 
hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-
(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any 
extent and whether or not substituted in the phenyl ring to any extent. 
 
Any compound structurally derived from 3-(1-adamantoyl) indole or 3-(2-
adamantoyl)indole by substitution at the nitrogen atom of the indole ring with alkyl, 
haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-
methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further 
substituted in the indole ring to any extent and whether or not substituted in the 
adamantyl ring to any extent. 
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Any compound structurally derived from  3-(2,2,3,3-
tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the 
indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, 
cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or 
not further substituted in the indole ring to any extent. 
 
No changes proposed for this generic definition: 
Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by 
substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, 
cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the 
cyclohexyl ring to any extent. 
 
Stereoisomers, esters, ethers and salts 
Schedule 2, Part 2 also includes any stereoisomers, ester or ether, salts, 
preparations and other products.
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Annex B 
 
Examples of Synthetic Cannabinoid Receptor Agonists not controlled by the 
Misuse of Drugs Act but which have been encountered in seizures or collected 
samples, or are available on websites, and which will be captured by the 
proposed revisions to the generic definition.  
 
Since the introduction in the UK of generic legislation in 2009 to control the synthetic 
cannabinoid receptor agonists, a number of new substances have appeared on the 
market that fall outside the scope of this legislation.  Compounds with a low affinity 
for the CB1 receptor (Ki > 100nM) would not normally be attractive to users as they 
would be more than 10x less potent than THC.  However, a number of new 
substances with low affinity for the CB1 receptor have been encountered in 
commercial products and are therefore included in the examples below: 
 
Compounds with haloalkyl sidechains 
 
AM-694 
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole 
 
 
 
Binding affinity: Ki (CB1) = 0.08nM; Ki (CB2) = 1.44nM 
Comments: 
1. EMCDDA Early Warning System Report 2010 - Collected samples of 
“Shamrock” herbal mixture from Head Shop in Dublin 
2. Makriyannis A, Deng H (2001) Cannabimimetic indole derivatives.  WO Patent 
2001/028557 A1, assignee University of Connecticut. 
3. Makriyannis A, Deng H (2001) Cannabimimetic indole derivatives.  US Patent 
2005/0119234 A1, assignee University of Connecticut. 
 
MAM-2201 
1-(5-fluoropentyl)-3-(4-methyl-naphthoyl)indole 
(4-methyl homologue of AM-2201) 
 
N
O
I
F
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Binding affinity: no data, but structure is related to JWH-122 [Ki (CB1) = 0.69 nM] and 
AM-2201 [Ki (CB1) = 1.0 nM]: 
Comments: 
1. EMCDDA Early Warning System Report 2011 - large seizure in the 
Netherlands 
2. EMCDDA Early Warning System Report 2011 – collected sample of herbal 
product “XoXo” in Germany. Also contained AM-2201 and reported to be 
available from www.goldkraut.com 
3. EMCDDA Early Warning System Report 2012 - two seizures in Finland mixed 
with AM-2201 
 
 
Compounds with (N-methylpiperidin-2-yl)methyl sidechains 
 
Cannabipiperidiethanone 
1-(N-methylpiperidin-2-yl)methyl-3-(2-methoxyphenylacetyl)indole 
1-(N-methylpiperidin-2-yl)methyl derivative of JWH-250  
 
 
Binding affinity: Ki(CB1) = 591nM; Ki(CB2) = 968nM 
 
 
 
 
 
 
Comments: 
1. EMCDDA Early Warning System Report in 2011: substance was found in 20 
different samples of herbal mixtures from Polish „smart shops‟ October 2010. 
The samples also contained JWH-122 and procaine. 
2. Identified in a herbal product in Japan together with JWH-122 and JWH-081 
Uchiyama N, Kikura-Hanajiri R, Goda Y (2011) Identification of a Novel 
Cannabimimetic Phenylacetylindole, Cannabipiperidiethanone, as a designed 
Drug in a Herbal Product and its affinity for cannabinoid CB1 and CB2 
receptors. Chem. Pharm. Bull. 59 (9), 1203-1205. 
 
 
 
 
 
AM-2233 
N
O
F
CH
3
N
O
N
OCH
3
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1-[(N-methylpiperidin-2-yl)methyl]-3-2-iodobenzoyl)indole 
 
 
 
Binding affinity: Ki (CB1) = 3.4 nM; Ki (CB2) = 7.6 nM [1] 
Comments: 
1. EMCDDA Early Warning System Report 2011 – seizure in Finland. 
2. Hongfeng Deng (2000) Design and synthesis of selective cannabinoid 
receptor ligands: Aminoalkylindole and other heterocyclic analogs. PhD 
Dissertation, University of Connecticut. 
 
AM-1220 
1-[(N-methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole 
 
 
Binding affinity: Ki (CB1) = 3.88 nM; Ki (CB2) = 73.4 nM 
Comments: 
1. EMCDDA Early Warning System Report 2011 – collected sample of herbal 
mixture (“Soulman”). Also contained AM-1220 azepane isomer. 
2. Makriyannis A, et al. (2008) Cannabimimetic Indole Derivatives, US Patent 
2008/0090871 
 
 
Benzoylindoles 
 
AM-679 
1-pentyl-3-(2-iodobenzoyl)indole 
 
N
O
I
N
N
O
N
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Binding affinity: Ki (CB1) = 13.5nM; Ki (CB2) = 49.5nM 
Comments: 
1. Was available from www.legalchem.co.uk  (this website no longer exists), was 
also available from other sites for example http://www.thrivechem.com/am-
679-40595-p.asp 
2. Makriyannis A, Deng H (2001) Cannabimimetic indole derivatives.  WO Patent 
2001/028557 A1, assignee University of Connecticut. 
3. Makriyannis A, Deng H (2001) Cannabimimetic indole derivatives.  US Patent 
2005/0119234 A1, assignee University of Connecticut. 
 
 
RCS-4 and the C4 homologue 
1-pentyl-3-(4-methoxybenzoyl)indole 
 
Binding affinity:  no data 
Comments: 
1. EMCDDA Early Warning System 2010 – seizure in Hungary 
 
 
RCS-4 2-isomer 
1-Pentyl-3-(2-methoxybenzoyl)indole 
  
Binding affinity: no data 
Comments: 
1. EMCDDA Early Warning System Report 2011 – seizure in Sweden 
2. Available from http://legalhighzone.com/rcs-4.html 
N
O
I
N
OMeO
N
O
CH
3
O
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WIN 48,098 (Pravadoline) 
1-(2-Morpholin-4-ylethyl)-2-methyl-3-(4-methoxybenzoyl)indole 
 
 
Binding affinity: Ki (CB1) = 3155 nM [2] 
Comments: 
1. EMCDDA Early Warning System Report 2010 - seizures of products labelled 
“GIT ROMAN” and “TWAWNIOL” in Poland from „smart shops‟. Other active 
ingredients included AM-694, JWH-081 and JWH-250 
2. EMCDDA Early Warning System Report 2011 – seizure of product labelled 
“Love” in Germany. Also contained AM-694 
 
  
Adamantoylindoles 
 
AM-1248 
3-(1-Adamantoyl)-1-(N-methylpiperidin-2-ylmethyl)indole 
 
 
 
Binding affinity: Ki (CB1) = 100 nM;  Ki (CB2) = 332 nM 
Comments: 
1. At least 2 vendors are reported to be selling this in the United States. 
Available from http://legalhighzone.com/am-1248.html  (lasted checked 
28/5/2012) 
2. Notification was received from the EMCDDA 26th Sept 2012 reporting AM-
1248 as an ingredient of „Annihilation‟ (the smoking mixture which has 
recently been reported to be causing problems amongst school children in the 
North of England.) 
http://www.thisislancashire.co.uk/news/9947927._Legal_high__puts_Darwen_
boy_in_hospital/ 
http://www.sunderlandecho.com/news/health/legal-high-taken-off-shelves-
after-substance-landed-teenager-in-hospital-1-4890988 
N
O
N
O
CH
3
OCH
3
N
O
N
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AB-001  
1-Pentyl-3-(1-adamantoyl)indole 
JW-018 adamantyl analogue  
 
 
Binding affinity: no data 
Comments: 
1. EMCDDA Early Warning System Report 2011 - collected samples of “Nuclear 
Reactor”, “Toxic Waste” and “Radio Active” herbal mixtures in Germany. 
NOTE: the structure shown in the EMCDDA report is actually the 2-
adamantoyl isomer 
 
3-(2,2,3,3-Tetramethylcyclopropylcarbonyl)indoles 
 
These are primarily CB2 agonists, but some have significant affinity for the CB1 
receptor. 
 
UR-144.  
1-Pentyl-3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole 
 
 
 
Ki(CB1) = 150nM 
 Frost, J.M. et al., (2010). Journal of Medicinal Chemistry, 53, 295-315. Available 
from: https://www.buyresearchchemicals.co.uk/cannabinoids/ur-144.html 
 
  
N
O
CH
3
N
O
CH
3
CH
3
CH
3
CH
3
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